Jonathan Fox

Jonathan C. Fox, MD, PhD, FACC, has served as President and Chief Medical Officer of Eidos since October 2016. Dr. Fox has served as the therapeutic area lead of cardiovascular and renal diseases at BridgeBio Pharma, LLC, since October 2016. Prior to that, from March 2013 to September 2016, Dr. Fox served as the chief medical officer of MyoKardia, Inc., and as a senior advisor from October 2016 to March 2017. He worked as a consultant at Nigel-Montgomery, LLC, from August 2012 to March 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories, and AstraZeneca LP from 1998 to 2012. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. He currently holds an adjunct faculty position at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his PhD in medicine and pathology, and his MD from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases, and is a Fellow of the American College of Cardiology.